PresentationAnd welcome to the next session. So it's sticking with -- we've got a European pharma afternoon, in fact, pharma biotech afternoon. So we have with Genmab and Anthony Pagano, who is the CFO. Anthony, I don't know if you wanted to make some sort of opening remarks, there's been obviously a lot going on for Genmab the last 6, 12 months, maybe just run through some key points, and then we'll get into some Q&A.Anthony PaganoExecutive VP & CFO Yes. Thanks, Graham. And again, thanks for having us at t ...

Core Insights - SystImmune, Inc., a wholly-owned subsidiary of Baillie Gifford (688506.SH), has received Breakthrough Therapy Designation from the FDA for izalontamabbrengitecan (iza-bren) for treating locally advanced or metastatic non-small cell lung cancer with specific mutations after prior treatments [1][2] Group 1 - The Breakthrough Therapy Designation is based on clinical research data from studies BL-B01D1-101, BL-B01D1-203, and BL-B01D1-LUNG-101, demonstrating the reliability of existing data [2] - The designation highlights the significant unmet clinical needs faced by patients after EGFR TKI and platinum-based chemotherapy, as most patients experience disease progression approximately 18 months after first-line treatment [2] - The FDA's Breakthrough Therapy Designation aims to expedite the development and review process for drugs that may significantly outperform existing standard therapies [2]